Fennec Pharmaceuticals Showcases PEDMARK Research at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy FENC?
Source: Newsfilter
- Clinical Research Highlights: Fennec Pharmaceuticals announced that four abstracts on PEDMARK® were accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the drug's potential in preventing cisplatin-induced ototoxicity, which is expected to enhance the company's market position in oncology.
- Drug Indication: PEDMARK® is FDA-approved for pediatric patients aged one month and older to reduce the risk of ototoxicity associated with cisplatin treatment, receiving a 2A recommendation from the National Comprehensive Cancer Network (NCCN), underscoring its significance in pediatric oncology.
- Presentation Schedule: The four studies will be presented at the ASCO meeting from May 29 to June 2, 2026, including randomized trials for various cancer patients, which are anticipated to attract industry attention and drive the market promotion of PEDMARK.
- Impact of Ototoxicity: Ototoxicity affects 60-90% of patients treated with cisplatin, and the introduction of PEDMARK offers a new treatment option for these patients, expected to improve quality of life and reduce long-term healthcare costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.900
Low
13.00
Averages
14.67
High
18.00
Current: 6.900
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fennec Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fennec Pharmaceuticals plans to release its Q1 2026 financial results before the U.S. market opens on May 14, 2026, with management hosting a conference call and webcast to discuss financial and business outcomes, which is expected to positively impact investor confidence.
- Call Timing and Links: The conference call is scheduled for 8:30 a.m. Eastern Time on May 14, and investors can access the live webcast link via the company’s website, ensuring connection at least 15 minutes prior to avoid technical issues, demonstrating the company's commitment to transparency and investor communication.
- PEDMARK® Commercialization Progress: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with FDA approval in 2022 and subsequent approvals in Europe and the U.K. in 2023, marking a strategic positioning in the oncology market.
- Exclusive Licensing Agreement: In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, which will further enhance Fennec's international market presence and sales potential.
See More
Fennec Pharmaceuticals Showcases PEDMARK Research at ASCO Meeting
- Clinical Research Highlights: Fennec Pharmaceuticals announced that four abstracts on PEDMARK® were accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the drug's potential in preventing cisplatin-induced ototoxicity, which is expected to enhance the company's market position in oncology.
- Drug Indication: PEDMARK® is FDA-approved for pediatric patients aged one month and older to reduce the risk of ototoxicity associated with cisplatin treatment, receiving a 2A recommendation from the National Comprehensive Cancer Network (NCCN), underscoring its significance in pediatric oncology.
- Presentation Schedule: The four studies will be presented at the ASCO meeting from May 29 to June 2, 2026, including randomized trials for various cancer patients, which are anticipated to attract industry attention and drive the market promotion of PEDMARK.
- Impact of Ototoxicity: Ototoxicity affects 60-90% of patients treated with cisplatin, and the introduction of PEDMARK offers a new treatment option for these patients, expected to improve quality of life and reduce long-term healthcare costs.
See More
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
Fennec Pharmaceuticals Reveals Investigator-Led Research to be Conducted by the University of Arizona Cancer Center
- Study Announcement: A sponsored study will be conducted by the University of Arizona Cancer Center.
- Focus of Research: The study aims to investigate specific aspects related to pharmaceuticals and cancer treatment.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 31, 2026, Fennec Pharmaceuticals granted a total of 377,500 incentive stock options to 24 new non-executive employees, with an exercise price of $5.77 per share, aimed at attracting talent and enhancing team stability.
- Inducement Plan Context: The stock options were granted under Nasdaq Listing Rule 5635(c)(4), specifically designed for individuals who were not previously employed by the company, reflecting the company's commitment to new hires and future growth.
- Option Structure: One-third of each option vests on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the next 24 months, ensuring employee retention and loyalty through continued employment.
- Market Outlook: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, and the exclusive licensing agreement with Norgine is expected to further expand market reach and enhance the company's competitive position in the pharmaceutical industry.
See More
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
Fennec Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fennec Pharmaceuticals plans to release its Q1 2026 financial results before the U.S. market opens on May 14, 2026, with management hosting a conference call and webcast to discuss financial and business outcomes, which is expected to positively impact investor confidence.
- Call Timing and Links: The conference call is scheduled for 8:30 a.m. Eastern Time on May 14, and investors can access the live webcast link via the company’s website, ensuring connection at least 15 minutes prior to avoid technical issues, demonstrating the company's commitment to transparency and investor communication.
- PEDMARK® Commercialization Progress: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with FDA approval in 2022 and subsequent approvals in Europe and the U.K. in 2023, marking a strategic positioning in the oncology market.
- Exclusive Licensing Agreement: In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, which will further enhance Fennec's international market presence and sales potential.
See More
Fennec Pharmaceuticals Showcases PEDMARK Research at ASCO Meeting
- Clinical Research Highlights: Fennec Pharmaceuticals announced that four abstracts on PEDMARK® were accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the drug's potential in preventing cisplatin-induced ototoxicity, which is expected to enhance the company's market position in oncology.
- Drug Indication: PEDMARK® is FDA-approved for pediatric patients aged one month and older to reduce the risk of ototoxicity associated with cisplatin treatment, receiving a 2A recommendation from the National Comprehensive Cancer Network (NCCN), underscoring its significance in pediatric oncology.
- Presentation Schedule: The four studies will be presented at the ASCO meeting from May 29 to June 2, 2026, including randomized trials for various cancer patients, which are anticipated to attract industry attention and drive the market promotion of PEDMARK.
- Impact of Ototoxicity: Ototoxicity affects 60-90% of patients treated with cisplatin, and the introduction of PEDMARK offers a new treatment option for these patients, expected to improve quality of life and reduce long-term healthcare costs.
See More
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
Fennec Pharmaceuticals Reveals Investigator-Led Research to be Conducted by the University of Arizona Cancer Center
- Study Announcement: A sponsored study will be conducted by the University of Arizona Cancer Center.
- Focus of Research: The study aims to investigate specific aspects related to pharmaceuticals and cancer treatment.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 31, 2026, Fennec Pharmaceuticals granted a total of 377,500 incentive stock options to 24 new non-executive employees, with an exercise price of $5.77 per share, aimed at attracting talent and enhancing team stability.
- Inducement Plan Context: The stock options were granted under Nasdaq Listing Rule 5635(c)(4), specifically designed for individuals who were not previously employed by the company, reflecting the company's commitment to new hires and future growth.
- Option Structure: One-third of each option vests on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the next 24 months, ensuring employee retention and loyalty through continued employment.
- Market Outlook: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, and the exclusive licensing agreement with Norgine is expected to further expand market reach and enhance the company's competitive position in the pharmaceutical industry.
See More
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
